Shinya Tokunaga

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 559 citations

Medicine, Oncology, Pharmacology +10

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

Kei Muro, Narikazu Boku, Yasuhiro Shimada et al. · The Lancet Oncology · 2010 · 219 citations

Medicine, Oncology, Pharmacology +13

Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers

Yoshinari Ogawa, Eishu Hai, Kanako Matsumoto et al. · International Journal of Clinical Oncology · 2008 · 182 citations

Medicine, Cancer Biology, Oncology +16

Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study

Yoichi Naito, Yuichiro Kai, Takashi Ishikawa et al. · Breast Cancer · 2019 · 61 citations · Full text

Medicine, Oncology, Breast Oncology +12

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial

Kazuhiro Nishikawa, Kazumasa Fujitani, Hitoshi Inagaki et al. · European Journal of Cancer · 2015 · 52 citations · Full text

Medicine, Oncology, Pharmacotherapy +16